Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Yan Zhang, Huiying Zhu, Zhangyuting He, Danqing Zhao, Chong Wei, Jing Ruan, Jian Li, Wei Zhang, Dao-Bin Zhou
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108713305